Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Los modelos preclínicos respaldan el potencial sinérgico del seralutinib y el sotatercept en el tratamiento de la hipertensión arterial pulmonar

Thursday, July 10, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Preclinical studies indicate that seralutinib and sotatercept may work synergistically in treating pulmonary arterial hypertension (PAH). This combination could enhance therapeutic outcomes, offering new hope for patients suffering from this condition. The findings underscore the importance of continued research in developing effective treatments for PAH.
Price reaction · baseline $1.36 (2025-07-09 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Preclinical models show synergistic potential of seralutinib and sotatercept.
  • The combination may improve treatment outcomes for pulmonary arterial hypertension.
  • Research suggests promising results in addressing this serious condition.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Los modelos preclínicos respaldan el potencial sinérgico del seralutinib y el sotatercept en el tratamiento de la hipertensión arterial pulmonar
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the focus of the preclinical models?

The preclinical models focus on the synergistic potential of seralutinib and sotatercept.

What condition are seralutinib and sotatercept targeting?

They are targeting pulmonary arterial hypertension (PAH).

What do the findings suggest about treatment outcomes?

The findings suggest that the combination may improve treatment outcomes for PAH.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib sotatercept pulmonary arterial hypertension preclinical models
Last updated: Jul 10, 2025

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →